Axsome Therapeutics

News

Elderly woman holds her head in her hands; black and white image

Axsome breaks new ground in Alzheimer's with Auvelity OK

Axsome's Auvelity has become the first non-antipsychotic therapy for agitation in patients with Alzheimer's disease to be approved by the FDA.

News

Axsome bounces back as FDA clears depression drug

Shares in Axsome Therapeutics have rocketed on FDA approval of its depression therapy Auvelity (formerly AXS-05) – a year after its approval was

News

Axsome faces delay for depression drug, hitting shares hard

The FDA was supposed to be delivering its verdict on Axsome Therapeutics' depression therapy AXS-05 in less than a fortnight – but instead has delivered the company a letter outlining defic

Axsome breaks new ground in Alzheimer's with Auvelity OK

Axsome bounces back as FDA clears depression drug

Axsome faces delay for depression drug, hitting shares hard

Novo sues Lilly over 'misleading' GLP-1 ad campaigning

Discover a new era of healthcare panel engagement: Grounded ...

Editor's Picks